BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7078-7081

  Treszezamsky, Alejandro D ^a   Kachnic, Lisa A ^b   Feng, Zhihui ^a,c   Zhang, Junran ^a,c   Tokadjian, Chake ^a   Powell, Simon N ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; ETOPOSIDE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG SPECIFICITY; GENETIC COMPLEMENTATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION;

ACLARUBICIN; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRCA1 PROTEIN; BRCA2 PROTEIN; CELLS, CULTURED; DNA BREAKS, DOUBLE-STRANDED; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; FIBROBLASTS; HUMANS;

EID: 34547617889     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0601     Document Type: Article

References (20)

1. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-9.
2. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-91.
3. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001;61:4842-50.
4. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. BRCA1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1996;12:191-4.
5. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-10.
6. Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-57.
7. Xia F, Taghian DG, DeFrank JS, et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A 2001;98:8644-9.
8. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:13560-6.
9. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991;51:4903-8.
10. Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N. Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks. Nucleic Acids Res 2003;31:4373-84.
11. Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived froma germ-line BRCA1 mutation carrier. Cancer Res 1998;58:3237-42.
12. Zhang J, Willers H, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates NA double-strand break repair. Mol Cell Biol 2004;24:708-18.
13. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
14. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903.
15. Bartz SR, Zhang Z, Burchard J, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006;26:9377-86.
16. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapyinduced apoptosis. Cancer Res 2003;63:6221-8.
17. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003;22:1169-73.
18. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978-85.
19. Muerkoster S, Arlt A, Witt M, et al. Usage of the NFnB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003;104:469-76.
20. Lou Z, Minter-Dykhouse K, Chen J. BRCA1 participates in DNA decatenation. Nat Struct Mol Biol 2005;12:589-93.